Pfizer advances clinical trials for 5- to 11-year-olds at lower doses

Pfizer is advancing Phase 2/3 clinical trials for young kids at lower doses than vaccines for adults, the pharmaceutical company announced Tuesday.

Pfizer is advancing Phase 2/3 clinical trials for young kids at lower doses than vaccines for adults, the pharmaceutical company announced Tuesday. Based on safety, efficacy and tolerability data from Pfizer's Phase 1 trial, the company will use 10 micrograms of each vaccine dose for kids between the ages of 5 and 11 in Phase 2/3 trials, and 3 micrograms of each dose for those 5 and younger. People ages 12 and older received 30 micrograms in each dose. In addition to studying vaccine safety and side effects in kids, the study will examine antibody response to ensure the vaccine produces enough immunity at lower doses. The study will include up to 4,500 participants from the United States, Finland, Poland and Spain, according to Pfizer.